Saquinavir Conference Data

Medical Advocates
Saquinavir (Fortovase/Invirase)

Conference Citations

17th CROI
Ninth Int. Congress on Drug Therapy in HIV Infection
4th IAS Conference
8th Int Congress on Drug Therapy in HIV Infection
XVI International AIDS Conference
7th International Workshop on Clinical Pharm of HIV
13th CROI
3rd IAS Conference
Archived Conferences

Saquinavir Main Page Main New/Newsworthy Home Page

Last Update: January 26, 2015
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
Perinatal data are in the Perinatal Data Page. Pediatric data are in the Pediatric Data Page

17th Conference on Retroviruses and
Opportunistic Infections

A Pharmacokinetic Study of Ritonavir-boosted Saquinavir in HIV-infected Children
4 Months to <6 Years Old
J Haznedar, A Zhang, E Labriola-Tompkins
Abstract

Ninth International Congress on Drug Therapy in HIV Infection

L76V – clinically relevant resensitization of the protease inhibitors (PIs) saquinavir (SQV) and atazanavir (ATV)
Vachta J, Wiesmann F, Braun P, et al
Abstract

4th IAS Conference on HIV Pathogenesis, Treatment
and Prevention

NEWS RELEASE
New Data Suggest Boosted Invirase Has Similar Efficacy to Boosted Lopinavir in HIV Patients at 24 Weeks
Roche
July 20, 2007

Saquinavir/r (SQV/r) BID vs lopinavir/r (LPV/r) BID plus emtricitabine/tenofovir (FTC/TDF) QD as
initial therapy in HIV-1 infected patients: the Gemini Study
Raffi F, Ward D, Ruxrungtham K, et al
Abstract

HIV-1 protease mutation L76V enhances susceptibility to atazanavir and saquinavir in multidrug-
resistant HIV-1 infected patients
Braun P, Wiesmann F, Walter H, et al
Abstract

14th Conference on Retroviruses and
Opportunistic Infections

POSTER
The Pharmacokinetics of Saquinavir in New Tablet Formulation + Ritonavir (1000/100 mg Twice Daily)
in HIV-1-infected Pregnant Women
D Burger, A Eggink, I Van der Ende, et al
PDF Poster Abstract
Effects of Atazanavir or Saquinavir Once Daily with Ritonavir 100 mg and Tenofovir/Emtricitabine as
Initial Therapy for HIV-1 Infection on Peripheral Glucose Disposal: A Randomized Open-label Study
A Jackson, N Patel, G Lo, et al
Abstract

8th Int Congress on Drug Therapy in HIV Infection

Saquinavir in double protease inhibitor regimens boosted with ritonavir (r) results of the AROMA-
cohort: comparison of saquinavir/atazanavir/r versus saquinavir/lopinavir/r
A Baumgarten
Abstract

Ritonavir boosted saquinavir once daily an Indian experience
S Kadappa, BRS Rao, G V Mallesh, et al
Abstract

Switching to saquinavir 500mg-based regimens maintains antiretroviral efficacy
T Mahungu, J Ballinger, L Swaden, et al
Abstract
The Rainbow Cohort: successful initiation/switch with/from the new saquinavir 500mg formulation
first results from Germany
H Knechten, T Lutz, G Knecht, A Haber. et al
Abstract
Effect of boosted saquinavir on the pharmacokinetics and pharmacodynamics of racemic
methadone in opiate-dependent patients on stable methadone maintenance therapy
C Jamois, M Riek, A Patel, et al
Abstract
Saquinavir/r (SQV/r) BID vs lopinavir/r (LPV/r) BID plus emtricitabine/tenofovir (FTC/TDF) QD
in ARV-nave HIV-1 infected patients: GEMINI Study
J Slim, A Avihingsanon, K Ruxrungtham, et al
Abstract
Trough concentrations in HIV patients receiving boosted hard-gel capsules (HGC) and
500mg film-coated tablet (FCT) formulations of saquinavir
L Dickinson, D Back, A Winston, et al
Abstract

XVI International AIDS Conference

Safety and efficacy of boosted saquinavir (SQV/r) in the rescue of patients with failure to HAART
including a non-boosted protease inhibitor
Sebastián G., López-Cortés L.F., Castaño M., et al
Abstract
Long-term efficacy and safety of once-daily ritonavir boosted-saquinavir mesylate (SQV/r) plus
2 NRTIs
Ananworanich J., Gayet-Ageron A., Hirschel B., et al
Abstract
Efficacy and safety of double boosted saquinavir (SQV)/lopinavir/ritonavir (LPV/r) in nucleoside
pre-treated children at 48 weeks
Kosalaraksa P., Bunupuradah T., Engchanil C., et al
Abstract

The HIV protease inhibitors nelfinavir and saquinavir induce epithelial apoptosis in normal and
malignant human colorectal mucosa and cancer cell lines
Lenzner L., Bode H., Krämer O.H., et al
Abstract

7th International Workshop on Clinical Pharmacology of
HIV Therapy

A WEEK-IN-REVIEW FEATURED REPORT
POSTER
Intra-patient variability and comparison of saquinavir/ritonavir Ctrough concentrations between
HIV-infected individuals and healthy volunteers administered saquinavir mesylate 500 mg film-
coated tablets (1000/100 mg twice daily).
L Dickinson , D Back, A Winston ,et al
PDF Poster

13th Conference on Retroviruses and
Opportunistic Infections

POSTER
Pharmacokinetics of Saquinavir with Low-dose Ritonavir or Atazanavir Twice Daily in Seronegative
Volunteers: ASPIRE II
J King, S Paul Lundy, T Kakuda, et al
PDF Poster Abstract

3rd IAS Conference

Resistance mutations in ARV-naïve patients treated with ritonavir-boosted saquinavir
J Ananworanich, K Ruxrungtham, S Sirivichayakul, et al
Abstract
Reduced rates of viral load suppression at six to 12 months by saquinavir and nelfinavir are
not solely explained by reduced adherence to therapy.
Moore D., Hogg R., Yip B., et al
Abstract
Hepatocellular toxicity in patients with HIV/TB co-infection receiving Rifampicin in combination
with Saquinavir and Ritonavir
Duran A., Lourtau L., Toibaro J., et al
Abstract

Saquinavir Main Page Main New/Newsworthy Home Page

Saquinavir Conference Reports, Abstracts, and Posters